Springworks Therapeutics, Inc. (SWTX) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1249708,
    "name": "Springworks Therapeutics, Inc.",
    "stock_name": "Springworks Therapeutics, Inc.",
    "full_name": "Springworks Therapeutics, Inc.",
    "name_url": "stocks-analysis/springworks-therapeutics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "46.99",
    "chg": "0.00",
    "chgp": "0.00%",
    "dir": 0,
    "prev_price": "46.99",
    "mcapval": "3,521.24",
    "mcap": "",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US85205L1070",
    "curr_date": "Jul 02",
    "curr_time": "",
    "bse_nse_vol": "0 ",
    "exc_status": "Active",
    "traded_date": "Jul 02, 2025",
    "traded_date_str": "2025 07 02",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/springworks-therapeutics-inc-1249708-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Springworks Therapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-springworks-therapeutics-inc-technically-bullish-or-bearish-3547868",
        "imagepath": "",
        "date": "2025-09-20 20:04:52",
        "description": "As of 23 June 2025, the technical trend for Springworks Therapeutics, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a bullish daily moving average and a bullish weekly RSI. However, the weekly MACD and KST are mildly bearish, indicating some caution. The Dow Theory shows a bearish signal on both weekly and monthly timeframes, which adds to the mixed signals. \n\nIn terms of performance, the stock has outperformed the S&P 500 year-to-date with a return of 30.06% compared to 12.22% for the index, and over one year, it returned 26.08% against the S&P's 17.14%...."
      },
      {
        "title": "Is Springworks Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-springworks-therapeutics-inc-overvalued-or-undervalued-3544101",
        "imagepath": "",
        "date": "2025-09-20 18:37:53",
        "description": "As of 27 February 2024, the valuation grade for Springworks Therapeutics, Inc. has moved from does not qualify to risky. The company appears to be overvalued based on its financial metrics, particularly given its high Price to Book Value of 8.45 and negative EV to EBITDA of -12.42. Additionally, the negative ROCE of -201.75% and ROE of -59.66% further indicate significant financial distress compared to its peers.\n\nIn the peer comparison, Springworks Therapeutics has a P/E ratio of -14.1396, while Biohaven Ltd. and Neumora Therapeutics, Inc. do not qualify for a P/E ratio, highlighting the relative riskiness of Springworks. The company’s recent stock performance shows a year-to-date return of 30.06%, which outpaces the S&P 500's return of 12.22%, suggesting some market optimism despite the underlying valuation concerns. Overall, Springworks Therapeutics is considered overvalued in the current market context...."
      }
    ],
    "total": 7,
    "sid": "1249708",
    "stock_news_url": "https://www.marketsmojo.com/news/springworks-therapeutics-inc-1249708"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Springworks Therapeutics, Inc. technically bullish or bearish?

2025-09-20 20:04:52

As of 23 June 2025, the technical trend for Springworks Therapeutics, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a bullish daily moving average and a bullish weekly RSI. However, the weekly MACD and KST are mildly bearish, indicating some caution. The Dow Theory shows a bearish signal on both weekly and monthly timeframes, which adds to the mixed signals. In terms of performance, the stock has outperformed the S&P 500 year-to-date with a return of 30.06% compared to 12.22% for the index, and over one year, it returned 26.08% against the S&P's 17.14%....

Is Springworks Therapeutics, Inc. overvalued or undervalued?

2025-09-20 18:37:53

As of 27 February 2024, the valuation grade for Springworks Therapeutics, Inc. has moved from does not qualify to risky. The company appears to be overvalued based on its financial metrics, particularly given its high Price to Book Value of 8.45 and negative EV to EBITDA of -12.42. Additionally, the negative ROCE of -201.75% and ROE of -59.66% further indicate significant financial distress compared to its peers. In the peer comparison, Springworks Therapeutics has a P/E ratio of -14.1396, while Biohaven Ltd. and Neumora Therapeutics, Inc. do not qualify for a P/E ratio, highlighting the relative riskiness of Springworks. The company’s recent stock performance shows a year-to-date return of 30.06%, which outpaces the S&P 500's return of 12.22%, suggesting some market optimism despite the underlying valuation concerns. Overall, Springworks Therapeutics is considered overvalued in the current market context....

View All News